Literature DB >> 29526543

Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.

Sarah A Best1, David P De Souza2, Ariena Kersbergen3, Antonia N Policheni4, Saravanan Dayalan2, Dedreia Tull2, Vivek Rathi5, Daniel H Gray4, Matthew E Ritchie6, Malcolm J McConville2, Kate D Sutherland7.   

Abstract

The lung presents a highly oxidative environment, which is tolerated through engagement of tightly controlled stress response pathways. A critical stress response mediator is the transcription factor nuclear factor erythroid-2-related factor 2 (NFE2L2/NRF2), which is negatively regulated by Kelch-like ECH-associated protein 1 (KEAP1). Alterations in the KEAP1/NRF2 pathway have been identified in 23% of lung adenocarcinomas, suggesting that deregulation of the pathway is a major cancer driver. We demonstrate that inactivation of Keap1 and Pten in the mouse lung promotes adenocarcinoma formation. Notably, metabolites identified in the plasma of Keap1f/f/Ptenf/f tumor-bearing mice indicate that tumorigenesis is associated with reprogramming of the pentose phosphate pathway. Furthermore, the immune milieu was dramatically changed by Keap1 and Pten deletion, and tumor regression was achieved utilizing immune checkpoint inhibition. Thus, our study highlights the ability to exploit both metabolic and immune characteristics in the detection and treatment of lung tumors harboring KEAP1/NRF2 pathway alterations.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Keap1; Nrf2; PD-L1; Pten; Taldo1; non-small-cell lung cancer

Mesh:

Substances:

Year:  2018        PMID: 29526543     DOI: 10.1016/j.cmet.2018.02.006

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  61 in total

1.  Studying the immune landscape in lung cancer models: choosing the right experimental tools.

Authors:  Clare E Weeden; Casey Ah-Cann; Marie-Liesse Asselin-Labat
Journal:  Transl Lung Cancer Res       Date:  2018-09

Review 2.  Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.

Authors:  Evert Njomen; Jetze J Tepe
Journal:  J Med Chem       Date:  2019-03-14       Impact factor: 7.446

3.  MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations.

Authors:  Sisheng Liu; Jinpeng Liu; Yanqi Xie; Tingting Zhai; Eugene W Hinderer; Arnold J Stromberg; Nathan L Vanderford; Jill M Kolesar; Hunter N B Moseley; Li Chen; Chunming Liu; Chi Wang
Journal:  Bioinformatics       Date:  2021-06-09       Impact factor: 6.937

4.  Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Authors:  Charu Aggarwal; Jeffrey C Thompson; Austin L Chien; Katie J Quinn; Wei-Ting Hwang; Taylor A Black; Stephanie S Yee; Theresa E Christensen; Michael J LaRiviere; Benjamin A Silva; Kimberly C Banks; Rebecca J Nagy; Elena Helman; Abigail T Berman; Christine A Ciunci; Aditi P Singh; Jeffrey S Wasser; Joshua M Bauml; Corey J Langer; Roger B Cohen; Erica L Carpenter
Journal:  Clin Cancer Res       Date:  2020-02-26       Impact factor: 12.531

5.  De novo NAD synthesis is required for intracellular replication of Coxiella burnetii, the causative agent of the neglected zoonotic disease Q fever.

Authors:  Mebratu A Bitew; Chen Ai Khoo; Nitika Neha; David P De Souza; Dedreia Tull; Nadeeka K Wawegama; Hayley J Newton; Fiona M Sansom
Journal:  J Biol Chem       Date:  2018-10-12       Impact factor: 5.157

6.  Profiling changes in metabolism and the immune microenvironment in lung tumorigenesis.

Authors:  Di Zhang; Ana S Leal; Fawzi Abu Rous; Karen T Liby
Journal:  Ann Transl Med       Date:  2019-07

7.  Function of hTim8a in complex IV assembly in neuronal cells provides insight into pathomechanism underlying Mohr-Tranebjærg syndrome.

Authors:  Yilin Kang; Alexander J Anderson; Thomas Daniel Jackson; Catherine S Palmer; David P De Souza; Kenji M Fujihara; Tegan Stait; Ann E Frazier; Nicholas J Clemons; Deidreia Tull; David R Thorburn; Malcolm J McConville; Michael T Ryan; David A Stroud; Diana Stojanovski
Journal:  Elife       Date:  2019-11-04       Impact factor: 8.140

8.  Cellular Nrf2 Levels Determine Cell Fate during Chemical Carcinogenesis in Esophageal Epithelium.

Authors:  Makoto Horiuchi; Keiko Taguchi; Wataru Hirose; Kouhei Tsuchida; Mikiko Suzuki; Yusuke Taniyama; Takashi Kamei; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2021-01-25       Impact factor: 4.272

9.  Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2.

Authors:  Liam Baird; Takafumi Suzuki; Yushi Takahashi; Eiji Hishinuma; Daisuke Saigusa; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2020-10-26       Impact factor: 4.272

Review 10.  "Keaping" a lid on lung cancer: the Keap1-Nrf2 pathway.

Authors:  Sarah A Best; Kate D Sutherland
Journal:  Cell Cycle       Date:  2018-08-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.